Most private equity ophthalmology platforms in this country were assembled in 2018 and 2019, and that timing is the entire story, even though almost nobody explains it to the physicians whose financial futures hang on it. A private equity fund holds a platform for a fixed window, typically 5 to 7 years, and then sells it, because the fund itself has a finite life and its investors expect their capital returned with a profit. The platforms built in 2018 and 2019 are now past that window. They're supposed to be selling. And for any physician sitting on rollover equity inside one of them, the problem is that the sales aren't happening the way the pitch promised.

If you're a physician weighing whether to leave a private-equity-owned practice, and the thing pinning you in place is equity you haven't been able to cash out, this is the math you need, because the bet you're being asked to keep holding has gotten meaningfully worse, and nobody on the platform's side has any incentive to walk you through it honestly.

How the Bet Is Supposed to Work

When private equity acquires a practice, the physician usually receives a mix of cash and rollover equity, frequently something in the neighborhood of 75% cash and 25% equity in the platform's holding company. The story told around that equity is the "second bite of the apple." Hold it, the narrative goes, and when the platform sells to the next buyer, your stake will be worth far more than it's today. That second payout is sold as the real reward for staying loyal and productive through the hold period.

The entire value of that promise depends on one event actually occurring on a knowable schedule: the platform selling, at a strong price, on a timeline you can plan your life around. Strip away the optimism and rollover equity is, in plain terms, a bet that a specific liquidity event will happen. If it happens on schedule and at a good valuation, the bet pays. If it slips, or happens at a discount, or your stake at the bottom of the capital stack gets consumed by debt repayment and preferred returns that sit ahead of you in line, the bet underperforms or pays nothing at all. The structure of that stack matters enormously, and physician common equity sits at the very bottom of it, behind the lenders, the preferred holders, and the sponsor's economics.

Why the Bet Is Failing Right Now

Here's what changed in the world while physicians kept holding their stakes. The platforms that should be selling can't find buyers on the old terms. Deal volume in private equity ophthalmology fell sharply, from roughly 75 transactions in 2021 to about 39 in 2022 by an analysis published in the American Journal of Ophthalmology and cited in Medscape's early-2026 coverage, with the broader slowdown continuing afterward. Higher interest rates made the debt-heavy private equity model both more expensive to operate and harder to exit cleanly. Consultants who work directly in the space, including longtime ophthalmology advisor John Pinto, have observed that only a small number of the anticipated secondary sales have actually closed. FOCUS Investment Banking, a sell-side firm that tracks this market closely and has every reason to be optimistic about deal activity, has nonetheless described most ophthalmology platforms as sitting at or past the end of their hold periods.

Stated plainly, the 2018 and 2019 platforms are stuck. They were built to be sold around now, and the buyers aren't lining up at the price the model assumed. For a physician holding rollover equity inside one of those platforms, that isn't an abstract market observation to file away. It's the direct, mechanical reason the payout you've been waiting for keeps failing to arrive, and may never land on any timeline you'd recognize as reasonable.

The Re-Roll the Pitch Leaves Out

Even when a platform does eventually sell, the second bite frequently isn't the clean payday it was advertised to be. Physicians are often required to re-roll a large portion of their equity into the new buyer's platform as a condition of the sale, which restarts the entire clock from zero: a new vesting schedule, a new multi-year hold period, another long stretch of illiquidity. The handcuff doesn't spring open when the platform sells. It transfers to a new owner and the waiting begins again. A Health Affairs Scholar study of private-equity-acquired practices found that the overwhelming majority of exits were secondary buyouts to other private equity firms rather than sales to long-term operators, which is exactly the pattern that produces a re-roll and a fresh clock rather than a clean cash-out and a door.

Reframing the Decision You Actually Face

Now hold the real choice in front of you, stripped of the pitch. The reason a physician stays in a private equity practice they want to leave is, almost always, the fear of forfeiting that rollover equity. Walking away feels like setting fire to a large pile of money. But examine what the money actually is. It's a bet on a liquidity event that, for the 2018 and 2019 vintage specifically, is delayed, uncertain, and may resolve into a re-roll that restarts the wait rather than a payout that ends it. It's a position at the bottom of a capital stack that gets paid last, if there's anything left to pay it with after the debt and the preferred returns take their share.

Staying starts to look like the dangerous choice once you see it clearly. Staying is continuing to hold a bet whose odds have visibly worsened, on a payout you don't control, while the years you could be spending building ownership of something that's actually yours slide past. The risk was never in leaving. It lives in waiting indefinitely for an event that the market is signaling, through collapsing deal volume and stalled exits, isn't reliably coming. That's the part the platform will never frame for you, because the platform's interest is in keeping you generating revenue while you wait, regardless of whether the wait ever pays.

None of this is a directive to walk out tomorrow. The decision to leave a contract is yours and your attorney's, and the specific terms of any individual agreement matter enormously to how that decision should go. The point here's narrower and more useful than advice. The thing you're afraid to forfeit may be worth far less, and pay far later, than you've been led to believe, and an honest accounting of the timing changes which choice actually carries the danger. Verdira's model offers the clean other side of that comparison: ownership of a practice you hold from the first day, with no exit clock and no liquidity event hanging over it, because the value comes from owning and running the practice rather than from waiting for someone else to eventually buy it out from under you.

This article is for general educational purposes and isn't financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a physician exploring ownership, we're open to thoughtful conversations. Contact info@verdira.com | 307-381-3734 | verdira.com Images are AI-generated illustrations and do not depict actual Verdira practices, physicians, or patients.